What is the recommended starting dose of atomoxetine?

Atomoxetine Starting Dose

For children and adolescents weighing ≤70 kg, start atomoxetine at 0.5 mg/kg/day; for those >70 kg and adults, start at 40 mg/day. 1

Weight-Based Dosing Algorithm

Children and Adolescents ≤70 kg

• Starting dose: 0.5 mg/kg/day
• Target dose: 1.2 mg/kg/day (reached after minimum 3 days)
• Administration: Either once daily in the morning OR divided into morning and late afternoon/evening doses
• Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is less 1

Children and Adolescents >70 kg and Adults

• Starting dose: 40 mg/day
• Target dose: 80 mg/day (reached after minimum 3 days)
• Administration: Either once daily in the morning OR divided into morning and late afternoon/evening doses
• Further titration: May increase to 100 mg/day after 2-4 additional weeks if optimal response not achieved
• Maximum dose: 100 mg/day 1

Critical Dosing Modifications

Hepatic Impairment

• Moderate hepatic insufficiency (Child-Pugh Class B): Reduce initial and target doses to 50% of normal dose
• Severe hepatic insufficiency (Child-Pugh Class C): Reduce initial and target doses to 25% of normal dose 1

CYP2D6 Poor Metabolizers or Strong Inhibitor Use

When patients are taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) or are known CYP2D6 poor metabolizers:

• Children ≤70 kg: Start at 0.5 mg/kg/day, increase to 1.2 mg/kg/day only if symptoms fail to improve after 4 weeks AND initial dose is well tolerated
• Children >70 kg and adults: Start at 40 mg/day, increase to 80 mg/day only if symptoms fail to improve after 4 weeks AND initial dose is well tolerated 1

Titration Strategy to Minimize Side Effects

The method of titration significantly impacts tolerability. Research demonstrates that slow titration with twice-daily dosing reduces early adverse events compared to rapid once-daily titration 2. Specifically:

• Slow/twice-daily titration (reaching 1.2 mg/kg/day over ≥2 weeks) resulted in lower rates of decreased appetite (8.0% vs 14.3%) and somnolence (4.2% vs 14.3%) compared to fast/once-daily titration (reaching target over 3 days) 2
• This approach is particularly important during the first 2 weeks of treatment when adverse events are most common

Important Clinical Considerations

Pre-Treatment Screening

Before initiating atomoxetine, screen for:

• Personal or family history of bipolar disorder, mania, or hypomania 1
• Personal and family cardiac history (sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome) 3
• If cardiac risk factors present, obtain ECG and consider cardiology referral 3

Common Pitfalls to Avoid

• Rapid dose escalation: This is the primary cause of early gastrointestinal symptoms and somnolence 3, 2
• Ignoring CYP2D6 status: Failure to adjust dosing for poor metabolizers or drug interactions can lead to excessive drug exposure and increased side effects 1
• Capsule manipulation: Atomoxetine capsules must be swallowed whole, not opened 1

Administration Flexibility

• May be taken with or without food
• Can be discontinued without tapering (unlike alpha-2 agonists) 1
• Dosing flexibility (once vs twice daily) allows optimization based on individual tolerability and symptom patterns

The FDA-approved dosing represents the authoritative standard, with research evidence from dose-response studies 4 confirming that 1.2 mg/kg/day is the optimal target dose, with no additional benefit demonstrated at higher doses.